HFNC vs. NIV in Acute COPD Exacerbations

NACompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

May 1, 2024

Conditions
COPD ExacerbationsAcute Hypercapnic Respiratory FailureRespiratory Failure
Interventions
DEVICE

NIV

The NIV group received bilevel-positive airway pressure. During NIV, the tidal volume was set to 6-8 mL/kg, positive expiratory end pressure (PEEP) to 3-5 cm H2O, and pressure support ventilation (PSV) to 8-12 cm H2O by a clinician with 8 years of experience. To reduce potential bias, the clinician was blinded to the null hypothesis.

DEVICE

HFNC-30

The HFNC-30 group received HFNC therapy at flow rates of 30 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.

DEVICE

HFNC-50

The HFNC-50 group received HFNC therapy at flow rates of 50 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.

Trial Locations (1)

34265

Haseki Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Haseki Training and Research Hospital

OTHER

NCT06495086 - HFNC vs. NIV in Acute COPD Exacerbations | Biotech Hunter | Biotech Hunter